Design of BET Inhibitor Bottlebrush Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities
Prodrugs engineered for preferential activation in diseased versus normal tissues offer immense potential to improve the therapeutic indexes (TIs) of preclinical and clinical-stage active pharmaceutical ingredients that either cannot be developed otherwise or whose efficacy or tolerability it is hig...
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
American Chemical Society (ACS)
2022
|
| Online Access: | https://hdl.handle.net/1721.1/141089 |